Lixiang Huang
Overview
Explore the profile of Lixiang Huang including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
36
Citations
248
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Tian Y, Chen J, Chen F, Xu J, Huang L, Peng L, et al.
Anal Chim Acta
. 2025 Jan;
1341:343662.
PMID: 39880501
Background: The threat of toxic malathion residues to human health has always been a serious food safety issue. The CRISPR/Cas system represents an innovative detection technology for pesticide residues, but...
2.
Lin W, Huang Y, Zhang Y, Huang L, Cai H, Huang G, et al.
Infect Agent Cancer
. 2025 Jan;
20(1):5.
PMID: 39875925
Background: It is crucial to identify post-operative patients with HPV infection who are at high risk for residual/recurrent disease. This study aimed to evaluate the association between HPV integration and...
3.
Su P, Mao X, Ma J, Huang L, Yu L, Tang S, et al.
J Exp Clin Cancer Res
. 2025 Jan;
44(1):23.
PMID: 39856770
No abstract available.
4.
Liu L, Ji X, Liang C, Zhu J, Huang L, Zhao Y, et al.
Future Oncol
. 2024 Sep;
:1-15.
PMID: 39287151
This study aimed to explore the importance of an MRI-based radiomics nomogram in predicting the progression-free survival (PFS) of endometrial cancer. Based on clinicopathological and radiomic characteristics, we established three...
5.
Chen L, Huang L, Gu Y, Li C, Sun P, Xiang Y
Int J Biol Macromol
. 2024 Jul;
277(Pt 1):133883.
PMID: 39033895
Tumour immunotherapy is an effective and essential treatment for cancer. However, the heterogeneity of tumours and the complex and changeable tumour immune microenvironment (TME) creates many uncertainties in the clinical...
6.
Su P, Mao X, Ma J, Huang L, Yu L, Tang S, et al.
J Exp Clin Cancer Res
. 2023 Oct;
42(1):274.
PMID: 37864196
Background: Tumor cells can resist chemotherapy-induced pyroptosis through glycolytic reprogramming. Estrogen-related receptor alpha (ERRα) is a central regulator of cellular energy metabolism associated with poor cancer prognosis. Herein, we refine...
7.
Shen L, Lu X, Wang H, Wu G, Guo Y, Zheng S, et al.
J Stroke Cerebrovasc Dis
. 2023 Oct;
32(12):107383.
PMID: 37844455
Objective: To measure the relative T1 (rT1) value in different hypo-perfused regions after ischemic stroke using T1 mapping derived by Strategically Acquired Gradient Echo (STAGE) and assess its relationship with...
8.
Lin X, Chen C, Jiang T, Ma J, Huang L, Huang L, et al.
Curr Oncol
. 2023 May;
30(4):3787-3799.
PMID: 37185400
Background: Metabolic dysfunction-associated fatty liver disease (MAFLD) is a significant health issue closely associated with multiple extrahepatic cancers. The association between MAFLD and clinical outcomes of endometrial cancer (EC) remains...
9.
Qin H, Huang L, Chen Y
Bull Environ Contam Toxicol
. 2023 May;
110(5):90.
PMID: 37149830
An integrated assessment of water environmental health risk through drinking water ingestion in Lhasa River has been implemented. The health risks caused by different pollutants in different age groups (children,...
10.
Li Y, Feng Y, Chen Y, Lin W, Gao H, Chen M, et al.
Virol J
. 2023 May;
20(1):80.
PMID: 37127618
Background: There is a close correlation between HPV infection and systemic immune status. The purpose of this study was to determine which lymphocytes in peripheral blood influence human papillomavirus (HPV)...